方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 回顾性II期临床试验× | III期临床试验× | |
|---|---|---|
| 领域 | 流行病学 | 流行病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1980s–1990s (with growth in oncology retrospective analyses) | 1962 (Kefauver-Harris Amendment formalised phased drug development) |
| 提出者≠ | Adapted from standard Phase II trial methodology; retrospective variant formalized in oncology practice | FDA regulatory framework / ICH guidelines |
| 类型≠ | Observational retrospective study | Confirmatory randomised controlled trial |
| 开创性文献≠ | Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10(1), 1–10. DOI ↗ | Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385 |
| 别名 | retrospective Phase II study, historical Phase II analysis, retrospective efficacy study, Phase II retrospective analysis | Phase 3 trial, confirmatory trial, pivotal trial, Phase III RCT |
| 相关≠ | 5 | 6 |
| 摘要≠ | A retrospective Phase II clinical trial evaluates a treatment's preliminary efficacy and safety signals using existing archival data — medical records, registries, or electronic health records — rather than prospectively enrolling new patients. It mirrors the objectives of a standard Phase II trial (estimating response rate, tolerability, and early efficacy) but does so by looking backward at patients who have already received the intervention, making it faster and less costly than a prospective design. | A Phase III clinical trial is a large-scale, confirmatory randomised controlled trial designed to establish the efficacy and safety of an intervention in the target patient population before regulatory submission. It builds on the signal identified in Phase II, tests the intervention at its proposed dose under controlled conditions, and provides the primary evidence base for marketing authorisation or guideline adoption. |
| ScholarGate数据集 ↗ |
|
|